Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VOYAGER dual-tracer fluorescence imaging study in inflammatory bowel disease
NL-OMON59621Phase 2Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of adalimumab and risankizumab in inflammatory bowel disease (IBD), autoimmune colitis and Crohn's disease (2 cohorts), sponsored by University Medical Center Groningen. Primary endpoints: Primary feasibility of dual-tracer fluorescence detection, Primary target-to-background and contrast-to-noise ratios and 3 more. Started May 2026; status: recruiting.
02
Drugs
adalimumabrisankizumab
03
Conditions
inflammatory bowel disease (IBD)autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on NL-OMON59621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59621.